Sugar signaling networks detected by high content fluxomics

描述（由申请人提供）：严格控制血糖水平对人体健康至关重要。细胞不断监测细胞外和胞质糖水平。细胞摄取和释放在肝脏和外周器官的适应是通过改变葡萄糖转运体和代谢酶的动力学特性来实现的。我们的目标是鉴定所有参与调节葡萄糖运输，代谢和区隔的基因，并通过通量组学揭示通量控制网络。对网络的理解为糖尿病、肥胖或癌症等健康相关疾病的干预提供了先进的基础。葡萄糖转运蛋白、己糖激酶和与葡萄糖和糖原代谢有关的酶是由基因家族编码的。这些构件的动力学性质不同。我们了解葡萄糖对胰腺胰岛素释放的间接影响，以及胰岛素作为器官间调节手段对葡萄糖转运活性的影响；我们对细胞基础上的糖信号知之甚少。多平行糖信号级联控制酵母代谢在美国，它们之间的相互作用还没有被完全理解。本项目旨在系统地推进利用通量组学在酵母和人类中识别信号网络。Frommer实验室开发了基因编码的FRET传感器，用于监测胞质葡萄糖水平的变化。纳米传感器可用于高通量筛选，以确定遗传变异的通量，即敲除和siRNA收集。微流控和微板平台被开发用于静态和动态筛网。该项目将在两种模型中系统地识别影响通量成分的基因：单细胞酵母酵母菌，以及作为肝癌和癌症模型的人类HepG2细胞。在筛选中发现的hit将使用FLIP传感器对其他糖、磷酸盐进行表征，并通过运输和代谢物分析。新发现的基因的作用将比较不同的人类细胞系，包括原代肝细胞。过表达和双突变/双siRNA将使糖信号网络的比较。该项目与糖尿病和肥胖（NIDDK）等代谢性疾病相关，并且由于糖对癌症（NCI）细胞增殖的重要性，以及由于葡萄糖水平改变而引起的其他疾病。该项目开发的网络和数据库有望为新药筛选提供新的方法，并有助于确定新的药物靶点。

DESCRIPTION (provided by applicant): Tight control over glucose levels is crucial for human health. Cells constantly monitor extracellular and cytosolic sugar levels. Acclimation of cellular uptake and release in liver as well as peripheral organs is achieved by changing the kinetic properties of glucose transporters and metabolic enzymes. Our goal is to identify all genes involved in regulating glucose transport, metabolism and compartmentation, and to unravel the flux control networks by fluxomics. The understanding of the networks provides an advanced base for intervention in health-related conditions such as Diabetes, obesity or cancer. Glucose transporters, hexokinases, and enzymes related to glucose and glycogen metabolism are encoded by gene families. The members differ in kinetic properties. We understand large parts of the indirect glucose effect on pancreatic insulin release and the effect of insulin in glucose transporrt activity as a means of inter-organ regulation; less is known about sugar signaling at the cellular basis. Multiparallel sugar signaling cascades control metabolism in yeast;, their interplay is not understood fully yet. This project intends to systematically advance the identification of the signaling networks using fluxomics in yeast and human. The Frommer lab developed genetically encoded FRET sensors for monitoring changes of cytosolic glucose levels. The nanosensors can be used in high-throughput screens to determine flux in genetic variants, i.e. knock-out and siRNA collections. Microfluidic and microplate platforms are developed for static and kinetic screens. The project will systematically identify genes affecting flux components in two models: the unicellular yeast Saccharomyces, and in human HepG2 cells as a model for liver and cancer. Hits identified in the screen will be characterized using FLIP sensors for other sugars, phosphate and by transport and metabolite analyses. The role of the newly identified genes will be compared in different human cell lines including primary hepatocytes. Overexpression and double mutant/double siRNA will enable comparison of sugar signaling networks. This project is relevant for metabolic diseases such as Diabetes and obesity (NIDDK), and due to the importance of sugars for cell proliferation for cancer (NCI), as well as other diseases that arise as a consequence of altered glucose levels. The networks and databases developed in this project promise to provide novel screening methods for novel drugs as well as help identifying new drug targets.